---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-24-000023"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:00:58.438763+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen FY2024 net loss narrows to $29.4M; fasedienol Phase 3 program on track

## Summary
- Net loss of $29.4M for FY2024, down from $59.2M in FY2023; cash and equivalents $119.2M as of March 31, 2024.
- R&D expenses decreased to $20.0M from $44.4M, primarily due to timing of fasedienol Phase 3 trials.
- PALISADE-3 Phase 3 trial for fasedienol in SAD initiated; PALISADE-4 expected in 2H 2024; positive PALISADE-2 results previously.
- Appointed Cindy Anderson as CFO; entered exclusive negotiation with Fuji Pharma to develop PH80 in Japan for menopausal hot flashes.
- Completed underwritten public offering to fund pipeline milestones; itruvone Phase 2B planning underway for MDD.

## SEC filing metadata
- accession: 0001411685-24-000023
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/0001411685-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000023/vtgn-20240611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-24-000023
- JSON: https://secwatch.observer/filing/0001411685-24-000023.json
- Plain text: https://secwatch.observer/filing/0001411685-24-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.